Head-To-Head Comparison: ZIVO Bioscience (NASDAQ:ZIVO) versus Ginkgo Bioworks (NYSE:DNA)

Ginkgo Bioworks (NYSE:DNA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ginkgo Bioworks and ZIVO Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	3	1	1	0	1.60
ZIVO Bioscience	0	1	0	0	2.00

Ginkgo Bioworks currently has a consensus target price of $4.58, indicating a potential downside of 62.84%. Given Ginkgo Bioworks’ higher probable upside, analysts clearly believe Ginkgo Bioworks is more favorable than ZIVO Bioscience.

Institutional & Insider Ownership

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Ginkgo Bioworks and ZIVO Bioscience”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$217.11 million	3.26	-$892.87 million	($13.08)	-0.94
ZIVO Bioscience	$15,850.00	4,620.38	-$7.78 million	($4.88)	-4.05

ZIVO Bioscience has lower revenue, but higher earnings than Ginkgo Bioworks. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ginkgo Bioworks has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500.

Profitability

This table compares Ginkgo Bioworks and ZIVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-298.78%	-58.54%	-34.24%
ZIVO Bioscience	N/A	N/A	-2,240.92%

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.